Plasma Microrna-Based Signatures To Predict 3-Year Postoperative Recurrence Risk For Stage Ii And Iii Gastric Cancer

Xinyang Liu,Xiaowei Zhang,Zhe Zhang,Jinjia Chang,Zhichao Wang,Zheng Wu,Chenchen Wang,Zuojun Sun,Xiaoxiao Ge,Ruixuan Geng,Wenbo Tang,Congqi Dai,Ying Lin,Fengjuan Lin,Menghong Sun,Weihua Jia,Wenqiong Xue,Jiafu Ji,Ying Hu,Guoyou Qin,Jin Li

DOI: https://doi.org/10.1002/ijc.30895

2017-01-01

International Journal of Cancer

Abstract:Our aim was to identify plasma microRNA (miRNA)-based signatures to predict 3-year postoperative recurrence risk for patients with stage II and III gastric cancer (GC), so as to provide insights for individualized adjuvant therapy. Plasma miRNA expression was investigated in three phases, involving 407 patients recruited from three centers. ABI miRNA microarray and TaqMan Low Density Array were adopted in the discovery phase to identify potential miRNAs. Quantitative reverse-transcriptase polymerase chain reaction was used to assess the expression of selected miRNAs. Logistic regression models were constructed in the training set (n=170) and validated in the validation set (n=169). Receiver operating characteristic analyses, survival analyses and subgroup analyses were further used to assess the accuracy of the models. We identified a 7 miRNA classifier and 7miR+pathological factors index that provided high predictive accuracy of GC recurrence (area under the curve=0.725 and 0.841 in the training set; and 0.627 and 0.771 in the validation set). High-risk patients defined by the signatures had significantly shorter disease-free survival and overall survival than low-risk patients. The 7 miRNA classifier is an independent prognostic factor, and could add predictive value to traditional prognostic factors. Subgroup analyses revealed the satisfactory performance persisted regardless of stage, and the two models both displayed high accuracy in stage IIA patients. In conclusion, identified microRNA signature may potentially provide some additional benefit for prediction of disease recurrence in patients with stage II and III GC.